SurgihoneyRO™ is an antimicrobial wound gel, a Class IIb medical device for the management of infected, chronic and acute wounds through to healing.
SurgihoneyRO™ is a unique, patented preparation that delivers Reactive Oxygen® to the wound bed. It has been proven to be effective against multi drug-resistant microorganisms commonly found in chronic wounds providing a solution in this era of antibiotic resistance.
|Matoke® Holdings Medical device division distributes SurgihoneyRO™ through its partner H&R Healthcare Ltd.
H&R Healthcare Ltd are UK distributors of the highest quality medical devices sourced from leading manufacturers throughout the world. Mike Hoskins, owner and Managing Director states, “SurgihoneyRO™ is an outstanding, disruptive technology that has the potential to transform the antimicrobial market, heal patients more quickly, and reduce antimicrobial prescribing”.
|Matoke® Holdings Ltd is developing its patented Reactive Oxygen® technology as novel treatments which are much more than conventional antibiotics through its pharmaceutical division, Matoke® Pharma. With the World Health Organisation predicting that millions may die due to global antimicrobial resistance (AMR), Reactive Oxygen® technology offers a potential solution to the global AMR threat which can help save lives.
Matoke® Holdings Ltd is a privately-owned UK- based company, a member of the BioIndustry Association (BIA) and registered Small to Medium-sized Enterprise (SME) with the European Medicines Agency (EMA).
Chief Executive and Founder
Ian Staples has had a distinguished executive career in the retail sector, including Managing Director of Halfords. He made the original discoveries on which Matoke® Holdings Ltd’s Reactive Oxygen® technology is based and has been instrumental in developing and bringing the CE marked medical device, SurgihoneyRO™, to market. His passion and drive has attracted a range of very high quality, committed and determined specialists to the team, to bring our medicinal product, RO™101, to market to transform the lives of patients throughout the world.
Brian McGowan is the Chairman of Matoke® Holdings Ltd, bringing a wealth of business experience to drive forward the business’ expansion. Brian co-founded Williams Holdings in 1982, which became one of the most successful companies of the 1980s and 1990s and included businesses such as Crown Paints, Polycell, Cuprinol, Kidde, Chubb, Thorn and Yale. After retiring from Williams in 1993 he became Chairman at House of Fraser plc, Rentokil plc, Umeco plc and Atlantra (previously Catalyst Corporate Finance).
Managing Director, Pharma Division
Alan Westwood is an anti-infective strategic specialist who formerly served as Vice President, Global Strategic Marketing, at Bayer. Alan is overseeing the research and development of RO™ 101 in the pharmaceutical division.
Andy Currie is a Non-Executive Director of Matoke® Holdings Ltd and is Managing Partner of Atlantra (previously Catalyst Corporate Finance). With a corporate finance career spanning over 25 years, Andy provides particular knowledge and expertise of Human Capital businesses, such as consultancies and professional services firms, and of advising private equity, bank consortia and other complex shareholder structures. An alumnus of Leicester University, Andy qualified as a Chartered Accountant with Price Waterhouse, (now PwC) and had a spell in industry with a listed building services firm prior to the formation of Catalyst in 1998.
Ian Jenkins is Matoke® Holdings Ltd’s Legal Counsel, and was the Senior Partner for 13 years of a City firm of solicitors with offices in London, Hong Kong and Shanghai. He also served as a non-executive director of a number of client companies, both public and private.
Dr Matthew Dryden
Chief Clinical Officer
Dr Matthew Dryden is a Clinical Director of Infection at the Hampshire Hospitals Trust, and the Rare and Imported Pathogens Department, Public Health England (PHE) and a senior lecturer at Southampton University Medical School. Recently he was General Secretary of the British Society for Antimicrobial Chemotherapy. His research interests include staphylococcal infection, skin and soft tissue infection, the development of new antibiotics, antibiotic stewardship, and the management of MRSA infections.
Professor Jonathan Cooke
Chief Scientific Officer
Professor Jonathan Cooke was Director of Research and Development and Chief Pharmacist at University Hospital of South Manchester, Honorary Professor, Manchester Pharmacy School, University of Manchester and Visiting Professor, Department of Medicine, Imperial College London. He has a specialist interest in antimicrobial resistance and was a member of the UK Department of Health’s Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection (ARHAI), Chair of the Antimicrobial Stewardship Committee and Advisor to WHO.
Managing Director, Medical Device Division
Mike Hoskins oversees Matoke® Holdings’ medical device division and the Managing Director of H&R Healthcare, which manages the distribution of SurgihoneyRO™. He has extensive experience in the medical device industry, having held Board level positions at Smith & Nephew and BSN Medical. He established H&R Healthcare in 2006, a leading distributor of third party wound management products in the UK, which has over 130 employees. Mike is also Chair of Onbone OY, a Finnish medical device manufacturer.